Innovation Pharmaceuticals has submitted a preliminary summary of Brilacidin’s therapeutic potential as a novel coronavirus treatment to the U.S. Government’s Biomedical Advanced Research and Development Authority (BARDA) and is already collaborating with scientists at the National Institute of Allergy and Infectious Diseases (NIAID) for review of Brilacidin as a potential COVID-19 intervention.